Boehringer Ingelheim Investigating Use of Therapy in 56,000 Patients With Atrial Fibrillation

Try Our New Player
tvnportal
1.5K
43 views
  • About
  • Export
  • Add to
Boehringer Ingelheim announced today the launch of the GLORIATM-AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.
Video provided by Business Wire
Producer : Business Wire

0 comments